ClinicalTrials.gg
RecruitingNCT07369024Updated Sep 2, 2026

Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

A Phase 2 interventional study of Sub-dissociative Ketamine Infusion and Normal Saline Placebo Infusion in Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease and Ketamine Infusion, sponsored by Mohsen Saidinejad. Recruiting at 1 site in United States. Open to participants aged 5 Years to 20 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Primary conditionVaso-Occlusive CrisesRegistry: Anemia, Sickle CellReclassifiedWhy we changed it
Registry
Anemia, Sickle Cell — the first condition term the registry derived for this study.
ClinicalTrials.gg
Vaso-Occlusive Crises
Why
  1. The study's listed conditions name Vaso-Occlusive Crises, a narrower term within Anemia, Sickle Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Mohsen Saidinejad · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
5 Years to 20 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 60 studies in Vaso-Occlusive Crises with a site in United States — 13 open to participants now, 15 under way, 5 of them phase 3. Vaso-Occlusive Crises · United States.

Planned enrollment
16th of 56
120 · median 63
Started
2026
with 4 others
Phase 2
18 of 60
4 open now
Primary completion
2027-12
later than 7 of 14 live
Registered
58th of 60
by date

Among the 60 studies in Vaso-Occlusive Crises with a site in United States, this one is the 16th largest by planned enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2026, is one of 18 in phase 2, reaches primary completion later than 7 of the 14 other live ones, and was the 58th registered.

Vaso-Occlusive Crises

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

Browse Vaso-Occlusive Crises studies →

Open to participants now

13 of the 60 studies in Vaso-Occlusive Crises with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Vaso-Occlusive Crises studies recruiting now, 7 (41%) set no upper age limit and 6 (35%) stop at 75 or younger; 10 take children under 18; 1 takes healthy volunteers.

This study: 5 Years to 20 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Vaso-Occlusive Crises with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an opioid such as morphine) plus a low dose (amount) of ketamine to those who receive only standard of care pain medicine.

03

Conditions studied

  • Sickle Cell Disease
  • Vaso-Occlusive Pain Episode in Sickle Cell Disease
  • Ketamine Infusion
  • Pain Management
  • Vaso-Occlusive Crises

Browse trials for

Keywords

  • Sickle Cell Disease
  • Vaso-Occlusive Pain Episode
  • Sub-Dissociative Ketamine
  • Pediatric Pain Management
04

In context

Vaso-Occlusive Crises Reclassified

104 studies on the registry are indexed under Vaso-Occlusive Crises; 31 are open to participants now.

This study's planned enrollment of 120 is above the median of 81 across 86 interventional studies indexed under Vaso-Occlusive Crises.

Browse Vaso-Occlusive Crises studies →

Lead sponsor

This is the only study on the registry with Mohsen Saidinejad as lead sponsor.

Compared within Vaso-Occlusive Crises, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Anemia, Sickle Cell. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
5 Years to 20 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between the ages 5-20 years
  • Diagnosed sickle cell disease. Homozygous (HbSS) or heterozygous (HbSC, HbSBetaThal Plus or Zero) will be included.
  • Presenting with VOE pain, requiring IV pain medication.
  • First dose of analgesic medication is given before patient approached for participation in the study.
  • Primary language is English or Spanish
  • Adult individual or parent/legal guardian is able and willing to provide . For individuals 7 to 17 years of age, assent must also be provided when cognitively possible.

Exclusion criteria

Exclusion Criteria:

  • Sickle cell trait only
  • Patients whose primary language is other than English or Spanish
  • Pain attributed to causes other than VOE
  • Not requiring IV for pain treatment
  • No analgesic (e.g. opiate) is given before approach for study participation due to any reason, including problem with IV access.
  • Oxygen saturation \< 90% on room air
  • History of prior adverse reaction to ketamine
  • History of hypertension - Patients with active/uncontrolled hypertension defined as systolic 140 mmHg over diastolic of 90 mmHg will be excluded from participation in the study. If hypertension is controlled and at the time of enrollment, systolic and diastolic thresholds of 140 mmHg and 90 mmHg respectively are not exceeded, patient may be included in the study
  • History of significant or uncontrolled cardiovascular disease, liver disease, kidney disease, and thyroid disease
  • Patients with evidence of increased intracranial pressure
  • Patients with elevated intraocular pressure
  • Patients with acute mania or history of bipolar disorder with manic episodes, history of hallucinations or paranoia secondary to previously diagnosed psychiatric condition
  • Pregnant or potentially pregnant patients per patient report. All patients of will undergo pregnancy testing prior to enrollment (as part of clinical care), and if positive, will be excluded.
  • Elevated liver enzymes (alkaline phosphatase, , AST, ) as sign of hepatic disfunction if the laboratory results are available prior to study participation
  • Patients who appear intoxicated on any substance.
  • Patients who are wards of the state or prisoners as defined by DHS
  • Patients who are not deemed to be competent to provide consent or assent.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Sub-dissociative Ketamine

    Participants receiving 0.25 mg/kg infusion of ketamine

    Drug: Sub-dissociative Ketamine Infusion

  • Placebo comparator
    Normal Saline

    Participants receiving 100 milliliters of normal saline

    Drug: Normal Saline Placebo Infusion

Interventions

  • DrugSub-dissociative Ketamine Infusion

    0.25 mg/kg of IV ketamine within a 20-minute infusion of 100 milliliters of normal saline (NS)

  • DrugNormal Saline Placebo Infusion

    20-minute infusion of 100 milliliters of normal saline

07

What researchers measure

Primary outcomes

  1. Total Opioid Medications Required for Analgesia

    Cumulative morphine-mg equivalent per kilogram (MME/kg) of opioid medication needed to achieve a pain score of ≤ 5

    Time frame: Up to 3 days

Secondary outcomes

  1. Pain Score

    Pain score from 0-10, at 30 and 60 minutes after administration of NS/placebo (control group), versus sub-dissociative ketamine (experimental group)

    Time frame: 30 minutes and 60 minutes after administration of placebo vs ketamine infusion

  2. ED Length of Stay

    To compare ED length of stay between control vs experimental group

    Time frame: Up to 3 days

  3. Rate of Hospitalization

    To compare rate of hospitalization and length of hospitalization between control and experimental group

    Time frame: Up to 1 month

  4. Quality of Life (Pediatric Quality of Life)

    To compare overall quality of life between the two groups upon discharge from the ED or the hospital, using the Pediatric Quality of Life (PedsQL) questionnaire. The questionnaire has 43 points and is reverse scored and linearly transformed to a 0-100 scale (0=100, 1=75, 2=50, 3=25, 4=0), so that higher scores indicate better quality of life.

    Time frame: 7-10 days after enrollment in the study and 4-6 weeks after enrollment in the study

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2026
First posted
Jan 27, 2026
StartEst.
Sep 10, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Apr 30, 2028
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07369024
Lead sponsor
Mohsen Saidinejad
Responsible party
Mohsen Saidinejad (Principal Investigator, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center) — Sponsor-investigator
First posted
Jan 27, 2026
Start date
Sep 10, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Cynthia Luo, MD
Contact
cluo2@dhs.lacounty.gov
310-222-2345
Mohsen Saidinejad, MD
Contact
moh@emedharbor.edu

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion